Advertisement
IDYA vs RNA
Which Stock Would AI Choose? IDEAYA Biosciences (IDYA) vs. Atrium Therapeutics (RNA) Stock Comparison
Key Takeaways
- IDYA is a clinical-stage precision oncology company with a lead asset nearing potential regulatory submission, while RNA is now Atrium Therapeutics, a preclinical cardiology biotech spun out of Avidity Biosciences.
- IDYA carries a Strong Buy analyst consensus and a large cash position, but remains deeply loss-making and recently pulled back from highs.
- RNA is a newly independent, early-stage company with a much smaller float and substantially higher volatility, including a steep decline in recent weeks.
- The two names differ sharply in maturity: IDYA is pursuing near-term commercial catalysts, whereas RNA's value rests on preclinical programs years from the market.
- Relative performance and risk profiles are driven less by shared sector exposure than by pipeline stage and corporate structure.
Introduction
Investors evaluating biotechnology often weigh companies at very different points along the drug-development lifecycle. This stock comparison puts two RNA and precision-medicine developers side by side: IDYA, a precision oncology specialist, and RNA, the ticker now held by Atrium Therapeutics following the acquisition of Avidity Biosciences. The contrast is instructive for growth-oriented traders and longer-horizon biotech investors alike, because it highlights how relative performance and market positioning can diverge between a late-stage, catalyst-rich name and a freshly listed preclinical company. Understanding each company's business model, momentum, and risk factors helps clarify where the balance of opportunity and uncertainty currently sits.
IDYA Overview and Recent Performance
IDYA, or IDEAYA Biosciences, is a precision medicine oncology company developing targeted therapies for patient populations selected through molecular diagnostics. Its pipeline is anchored by darovasertib for metastatic uveal melanoma, where the company has been advancing an NDA (New Drug Application) submission with Fast Track designation, alongside earlier-stage assets such as IDE849 targeting DLL3 in small cell lung cancer and IDE892, a PRMT5 inhibitor for MTAP-deleted solid tumors.
In recent market activity, IDEAYA has experienced a choppy phase, pulling back from levels reached earlier in the year even as its longer-term trajectory remains positive. The company reported modest revenue against widening net losses in its latest quarter, consistent with a business still investing heavily in research and development (R&D). A leadership change concentrated R&D responsibility in a single executive, and the company announced a clinical collaboration with Roche. Analysts have largely maintained Buy ratings, with a consensus price target above recent trading levels, reflecting conviction in the pipeline despite near-term execution risk. A cash balance of roughly $1.2 billion provides an extended runway.
RNA Overview and Recent Performance
RNA is now the ticker for Atrium Therapeutics, a biotechnology company formed through the spin-off of Avidity Biosciences' early-stage precision cardiology programs. The change followed the completion of Novartis' roughly $12 billion acquisition of Avidity in early 2026, with Atrium inheriting the Nasdaq symbol. The company is developing RNA-based therapies, specifically small interfering RNA (siRNA) approaches, for rare genetic cardiomyopathies.
Atrium's pipeline is entirely preclinical, led by ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. It launched with approximately $270 million in cash and has since completed a private placement financing, underscoring ongoing capital needs. In recent weeks, the stock has shown pronounced volatility and a meaningful decline, reflecting both the typical selling pressure that follows a spin-off and the inherent uncertainty of preclinical-stage assets. Atrium holds collaboration agreements with Bristol Myers Squibb and Eli Lilly, and its first IND (Investigational New Drug) filing is anticipated in the near term, marking an early milestone investors are watching.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots, selected for their suitability to current market conditions. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance metrics, and basket of securities. Because no single approach fits every market environment, only the best-performing and most appropriate robots earn a place in this featured section. For traders comparing names such as IDYA and RNA, reviewing how AI models rank trend consistency, volatility, and relative momentum can add a data-driven layer to their analysis. Explore the Trending AI Robots section to see which strategies are currently favored.
Head-to-Head Comparison
The most fundamental contrast between IDYA and RNA is pipeline maturity. IDEAYA is positioned closer to potential commercialization, with a lead candidate in registrational-stage development and multiple clinical programs, whereas Atrium's entire pipeline remains preclinical. This gap directly shapes each company's risk profile and market positioning.
Growth drivers also differ. IDYA's near-term catalysts center on regulatory filings and clinical readouts across oncology, supported by a broad balance sheet and strong sell-side support. RNA's drivers are earlier-stage: IND filings, initial human data, and partnership economics in a niche cardiology field. Recent momentum has been mixed for both, but the scale of volatility is not comparable—Atrium's small float and recent financing have amplified price swings, while IDEAYA's pullback has been more moderate against a longer positive trend.
On sector exposure, both are biotechnology, yet their sub-sectors—oncology versus rare cardiac disease—carry different competitive and regulatory dynamics. Sentiment toward IDYA leans constructive on pipeline breadth and capital strength, while sentiment toward RNA reflects the uncertainty of a newly independent, pre-revenue entity. These contrasts make the two names more complements than direct competitors in a diversified biotech view.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely favor IDYA over RNA in the current environment. IDEAYA combines a more advanced pipeline, a stronger analyst consensus, and a substantially larger cash runway, which tends to support more stable relative performance despite ongoing losses. Atrium, by contrast, carries higher volatility and earlier-stage execution risk, which can make its trend signal less reliable for momentum-oriented models. This is a probabilistic assessment rather than a definitive prediction: both stocks remain subject to clinical, regulatory, and financing risks, and AI-driven rankings can shift as new data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RNA is a StrongBuy.
IDYA's Indicator enters downward trend
The Aroon Indicator for IDYA entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 241 similar instances where the Aroon Indicator formed such a pattern. In 201 of the 241 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 86 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
IDYA moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IDYA crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IDYA's RSI Oscillator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where IDYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 218 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (2.988). P/E Ratio (-18.812) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RNA sees its Stochastic Oscillator ascends from oversold territory
On October 21, 2026, the Stochastic Oscillator for RNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 49 instances where the indicator left the oversold zone. In 43 of the 49 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNA's RSI Indicator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on RNA as a result. In 64 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for RNA just turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.638) is normal, around the industry mean (2.988). P/E Ratio (-1.471) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IDYA | RNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 78 | 100 | |
SMR RATING 1..100 | 94 | 97 | |
PRICE GROWTH RATING 1..100 | 49 | 85 | |
P/E GROWTH RATING 1..100 | 40 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDYA's Valuation (11) in the null industry is in the same range as RNA (36). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
IDYA's Profit vs Risk Rating (78) in the null industry is in the same range as RNA (100). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
IDYA's SMR Rating (94) in the null industry is in the same range as RNA (97). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
IDYA's Price Growth Rating (49) in the null industry is somewhat better than the same rating for RNA (85). This means that IDYA’s stock grew somewhat faster than RNA’s over the last 12 months.
RNA's P/E Growth Rating (15) in the null industry is in the same range as IDYA (40). This means that RNA’s stock grew similarly to IDYA’s over the last 12 months.
| IDYA | RNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 75% |
| MACD ODDS (%) | N/A | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| Advances ODDS (%) | 2 days ago 75% | 2 days ago 78% |
| Declines ODDS (%) | 7 days ago 76% | 4 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 76% | N/A |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDYA’s FA Score shows that 1 FA rating(s) are green while RNA’s FA Score has 1 green FA rating(s).
- IDYA’s FA Score: 1 green, 4 red.
- RNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDYA’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 5 bullish TA indicator(s).
- IDYA’s TA Score: 4 bullish, 5 bearish.
- RNA’s TA Score: 5 bullish, 2 bearish.
Price Growth
IDYA (@Biotechnology) experienced а +4.75% price change this week, while RNA (@Biotechnology) price change was +4.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
IDYA is expected to report earnings on Nov 03, 2026.
RNA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PSI | 129.12 | 2.93 | +2.32% |
| Invesco Semiconductors ETF (PSI) | |||
| VCLN | 26.04 | 0.34 | +1.33% |
| Virtus Duff & Phelps Clean Energy ETF (VCLN) | |||
| XOCT | 40.69 | 0.08 | +0.20% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - October (XOCT) | |||
| BRHY | 49.17 | 0.01 | +0.02% |
| iShares High Yield Active ETF (BRHY) | |||
| VCV | 8.88 | -0.03 | -0.34% |
| INVESCO CALIFORNIA VALUE MUNI Income TRUST | |||